|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019721,
umls-concept:C0037791,
umls-concept:C0039194,
umls-concept:C0042196,
umls-concept:C0205263,
umls-concept:C0456387,
umls-concept:C0871261,
umls-concept:C1134528,
umls-concept:C1140680,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
31
|
|
pubmed:dateCreated |
2007-8-1
|
|
pubmed:abstractText |
NY-ESO-1 is a "cancer-testis" antigen expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date. The NY-ESO-1 peptide epitope, ESO(157-170), is recognized by HLA-DP4-restricted CD4+ T cells and HLA-A2- and A24-restricted CD8+ T cells. To test whether providing cognate helper CD4+ T cells would enhance the antitumor immune response, we conducted a phase I clinical trial of immunization with ESO(157-170) mixed with incomplete Freund's adjuvant (Montanide ISA51) in 18 HLA-DP4+ EOC patients with minimal disease burden. NY-ESO-1-specific Ab responses and/or specific HLA-A2-restricted CD8+ and HLA-DP4-restricted CD4+ T cell responses were induced by a course of at least five vaccinations at three weekly intervals in a high proportion of patients. There were no serious vaccine-related adverse events. Vaccine-induced CD8+ and CD4+ T cell clones were shown to recognize NY-ESO-1-expressing tumor targets. T cell receptor analysis indicated that tumor-recognizing CD4+ T cell clones were structurally distinct from non-tumor-recognizing clones. Long-lived and functional vaccine-elicited CD8+ and CD4+ T cells were detectable in some patients up to 12 months after immunization. These results confirm the paradigm that the provision of cognate CD4+ T cell help is important for cancer vaccine design and provides the rationale for a phase II study design using ESO(157-170) epitope or the full-length NY-ESO-1 protein for immunotherapy in patients with EOC.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-10070965,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-11005863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-11027314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-11454878,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-12097265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-12138174,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-12186971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-12488431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-12529460,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-12538675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-12853579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-14522938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-14871964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-15252201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-15534491,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-15838382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-16344461,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-16393950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-16394300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-16670346,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-16984998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-17517626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-2137372,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-7500015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-8766577,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-9050879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-9432985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17652518-9624004
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
pubmed-author:AndrewsChristopherC,
pubmed-author:GnjaticSachaS,
pubmed-author:HoffmanEric WEW,
pubmed-author:LeleShashikantS,
pubmed-author:MatsuzakiJunkoJ,
pubmed-author:Mhawech-FaucegliaPauletteP,
pubmed-author:OdunsiKunleK,
pubmed-author:OldLloyd JLJ,
pubmed-author:PanLindaL,
pubmed-author:QianFengF,
pubmed-author:RitterGerdG,
pubmed-author:RodabaughKerryK,
pubmed-author:ShrikantProtulP,
pubmed-author:ThomasBridgetB,
pubmed-author:VillellaJeannineJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
31
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
12837-42
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17652518-Antibodies,
pubmed-meshheading:17652518-Antibody Formation,
pubmed-meshheading:17652518-Cancer Vaccines,
pubmed-meshheading:17652518-Female,
pubmed-meshheading:17652518-Freund's Adjuvant,
pubmed-meshheading:17652518-Histocompatibility Antigens Class I,
pubmed-meshheading:17652518-Histocompatibility Antigens Class II,
pubmed-meshheading:17652518-Humans,
pubmed-meshheading:17652518-Neoplasm Proteins,
pubmed-meshheading:17652518-Ovarian Neoplasms,
pubmed-meshheading:17652518-Peptide Fragments,
pubmed-meshheading:17652518-T-Lymphocytes
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
|
|
pubmed:affiliation |
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. kunle.odunsi@@roswellpark.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
